{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-135207","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2024-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.752912+00:00","generated_at":"2026-05-29T04:47:02.519604+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Relay Therapeutics reports RLY-2608+fulvestrant median PFS 11.4 months in 2L breast cancer; plans pivotal study in 2025","bullets":["Median PFS 9.2 months overall, 11.4 months in 2L patients at RP2D (600mg BID) without PTEN/AKT co-mutations.","Confirmed ORR 39% overall, 67% in kinase-mutation patients; CBR 67%; median follow-up 9.5 months.","Low discontinuation rate (2 patients due to TRAEs); 94% median dose intensity; only 3% Grade 3 hyperglycemia.","Cash and investments ~$840M as of Q3 2024; funds 2L pivotal study planned for 2025.","Triplet combinations with ribociclib (ongoing) and atirmociclib (initiated) progressing; VMs study in Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-135207","json":"https://secwatch.observer/filing/0000950170-24-135207.json","markdown":"https://secwatch.observer/filing/0000950170-24-135207.md","text":"https://secwatch.observer/filing/0000950170-24-135207.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024135207/0000950170-24-135207-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024135207/rlay-20241211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T04:47:02.519604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}